CORT ALERT: Ongoing Investigation Into Corcept Therapeutics Incorporated - Contact Levi & Korsinsky

New York, New York--(Newsfile Corp. - February 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ: CORT) concerning potential violations of the federal securities laws.

What Happened?

On December 31, 2025, Corcept announced it received a CRL from the FDA, denying approval of Corcept's new drug application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
According to the Company's release, the FDA acknowledged the results of the previous GRACE and GRADIENT drug trials, but "concluded it could not arrive at a favorable benefit-risk assessment for relacordilant without Corcept providing additional evidence of effectiveness"

Why it Matters:

Today, in direct response to this news, Corcept's stock price fell by $31.42 (44.76%) per share to open at $38.78 per share on December 31, 2025.
This drop marks a new 52-week low for Corcept's stock, dropping to levels not seen since September 2024.

If you suffered a loss on your Corcept Therapeutics Incorporated securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [e-mail] or call [phone] to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[e-mail]
Tel: [phone]
Fax: [phone]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284013

The Corcept Therapeutics Stock at the time of publication of the news with a raise of +4,25 % to 39,97EUR on Nasdaq stock exchange (14. Februar 2026, 02:00 Uhr).